Moteur de recherche d’entreprises européennes
Financement de l’UE (3 887 260 €) : Signatures de sécurité vaccinale et d’immunogénicité des réponses humaines au VSV-ZEBOV – Réf. Sofia : 115842 Hor01/03/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Signatures de sécurité vaccinale et d’immunogénicité des réponses humaines au VSV-ZEBOV – Réf. Sofia : 115842
The proposal, VSV-EBOVAC, directly addresses the topic 1 of the IMI2 call on Ebola by supporting the clinical development of a highly promising new Ebola vaccine candidate, the vesicular stomatitis virus (VSV)‐ vectored Zaire Ebola vaccine (VSV-ZEBOV). In non-human primates, a single dose of VSV-ZEBOV elicited a strong (100%) and long-lasting protective efficacy against Ebola Zaire infections. Developed by Public Health Canada and manufactured by NewLink Genetics, VSV-ZEBOV was thus selected by the World Health Organization (WHO) as one of the 2 most promising vaccine candidates. To accelerate its clinical development, the WHO has organized a consortium and supported the organization of parallel first-in-man Phase I/II clinical trials, both in Europe and Africa. The primary objectives of these trials, initiated mid-November 2014, are to study the safety and antibody-inducing capacity of various doses of VSV-ZEBOV in European and African populations. We propose to build upon this asset to acquire new and critical knowledge of the innate and adaptive immune responses elicited in humans by VSV-ZEBOV vaccination, with specific emphasis on trancriptomics and metabolomics signatures. To this aim, we have constructed a consortium including representatives from the vaccine manufacturer, scientists of the 3 main clinical sites (Switzerland, Gabon, Kenya) and world-leaders in immunology and partners of ADITEC, a large FP7- supported collaborative research programme aiming to accelerate the development of novel, powerful immunisation technologies for next-generation vaccines. We propose an ambitious program using cutting-edge technologies to perform an in depth characterization of the clinical samples harvested before/after VSV-ZEBOV immunization of 200 volunteers in Switzerland, Gabon and Kenya, and to extend the recently initiated clinical studies up to 12 months to identify the signatures and determinants of persistent immune responses.
| ACADEMISCH ZIEKENHUIS LEIDEN | 522 552 € |
| BIOPROTECTION SYSTEMS CORPORATION | 62 500 € |
| Centre de Recherches Medicales de Lambaréné | 118 875 € |
| Department of Health | 125 000 € |
| EBERHARD KARLS UNIVERSITAET TUEBINGEN | 9 375,00 € |
| EIDGENOSSISCHES DEPARTEMENT FUR VERTEIDIGUNG, BEVOLKERUNGSSCHUTZ UND SPORT | 0,00 € |
| EMORY UNIVERSITY NON PROFIT Corp. | 600 888 € |
| Goeteborgs Universitet | 700 000 € |
| Microbiotec Srl | 212 500 € |
| Sclavo Vaccines Association | 841 250 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 131 820 € |
| Universita Degli Studi Di Siena | 562 500 € |
| UNIVERSITE DE GENEVE | 0,00 € |
https://cordis.europa.eu/project/id/115842
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.